Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Metabolic signature of idiopathic inflammatory myopathy

ABSTRACT: Objective of this study was to find Metabolic signature of idiopathic inflammatory myopathy (IIM). We used the serum samples of healthy control, IIM, ankylosing spondylitis. Metabolites were quantified using biocrates p180 kit. First, we found IIM specific metabolites by using ANOVA with post-hoc analysis. With set of metabolite panel, we made prediction model using logistic regression (LR), support vector machine (SVM), and random forest (RF). We found 7 metabolites as biomarker for classifying IIM from healthy control and ankylosing spondylitis. Also, we validate our model using 5 cross validation method. Out set of metabolites showed the AUC values of 0.955 (LR), 0.908 (RF) and 0.918 (SVM).

ORGANISM(S): Human Homo Sapiens

TISSUE(S): Blood

DISEASE(S): Inflammation

SUBMITTER: Jihyun Kang

PROVIDER: ST002196 | MetabolomicsWorkbench | Thu Jun 09 00:00:00 BST 2022

REPOSITORIES: MetabolomicsWorkbench

ACCESS DATA

Json Xml

Similar Datasets

Convergence of plasma metabolomics and proteomics analysis to discover signatures of high-grade serous ovarian cancer

Project description:The purpose of this study is to find candidate biomarkers by analyzing metabolites and proteins with differential amounts in 10 ovarian cancer patient plasmas and 10 healthy female plasmas. Only MS files for plasma proteins are uploaded here. The metabolite quants were obtained using Biocrates AbsolutedIDQ p400, and MS data was not uploaded but only the quantitative value table was uploaded.

2020-12-01 | PXD020557 | Pride

Metabolic signature of C-protein induced myositis mouse model

Project description:Objective of this study was to find Metabolic signature of C-protein induced myositis mouse model. For metabolite quantification, we used the tissue samples of C-protein induced myositis mouse model and control. Biocrates p180 kit enables to quantify 188 metabolites including amino acids, biogenic amines, acylcarnitine, glycerophospholipid and sugar. Significant metabolites were selected by t-test with false discovery rate p-value less than 0.05. In mouse tissue sample, a total of 68 metabolites significantly changed in CIM mice. We did pathway analysis to find altered pathway in muscle tissue. Metabolites from polyamine and beta-alanine pathway were altered.

2022-06-15 | ST002197 | MetabolomicsWorkbench

Metabolomics of Mice Cohousing and Microbiota Transfer

Project description:The mice serum samples were extracted and prepared for a combined flow injection (FIA) and LC-MS/MS assay (Biocrates AbsoluteIDQ® p180 kit). The Biocrates AbsoluteIDQ® p180 kit (Biocrates Life Sciences AG, Innsbruck, Austria) can quantitatively measure ~188 biologically relevant metabolites from five analyte groups (acylcarnitines, amino acids, biogenic amines, glycerophospho- and sphingolipids, and hexoses) on a triple quadrupole mass spectrometer.

2016-09-01 | ST000457 | MetabolomicsWorkbench

AI Prediction Model and Risk Stratification for Lung Metastasis in Colorectal Cancer

Project description:Background: To assist clinicians with diagnosis and optimal treatment decision-making, we attempted to develop and validate an artificial intelligence prediction model for lung metastasis (LM) in colorectal cancer (CRC) patients. Method: The clinicopathological characteristics of 46037 CRC patients from the Surveillance, Epidemiology, and End Results (SEER) database and 2779 CRC patients from a multi-center external validation set were collected retrospectively. After feature selection by univariate and multivariate analyses, six machine learning (ML) models, including logistic regression, K-nearest neighbor, support vector machine, decision tree, random forest, and balanced random forest (BRF), were developed and validated for the LM prediction. The optimization model with best performance was compared to the clinical predictor. In addition, stratified LM patients by risk score were utilized for survival analysis.

| 46649 | ecrin-mdr-crc

Tuberculosis diagnostic biomarker signature by proteomics and metabolomics

Project description:: Tuberculosis (TB) is a transmissible disease listed as one of the 10 leading causes of death worldwide (10 million infected in 2019). A swift and precise diagnosis is essential to forestall its transmission, for which is crucial the discovery of effective diagnostic biomarkers. In this study, we aimed to discover molecular biomarkers for the early diagnosis of tuberculosis. Two independent cohorts comprising 29 and 34 subjects were assayed by proteomics, and 49 were included for metabolomic analysis. All subjects were arranged into 3 experimental groups – healthy controls (Controls), Latent TB infection (LTBI) and TB patients. LC-MS/MS blood serum protein and metabolite levels were submitted to univariate, multivariate and ROC analysis. From the 149 proteins quantified in the discovery set, 25 were found to be differentially abundant between Controls and TB patients. The AUC, specificity and sensitivity, determined by ROC statistical analysis of the model composed by four of these proteins considering both proteomic sets, were 0.96; 93% and 91%, respectively. The five metabolites (9-methyluric acid, indole-3-lactic acid, trans-3-indoleacrylic acid, hexanoylglycine and N-acetyl-L-leucine) that better discriminate the control and TB patient groups (VIP > 1.75) from a total of 92 metabolites quantified in both ionization modes, were submitted to ROC analysis. An AUC=1 was determined with all samples being correctly assigned to the respective experimental group. An integrated ROC analysis enrolling 1 protein and 4 metabolites was also performed for the common control and TB patients in the proteomic and metabolomic groups. This combined signature has correctly assigned the 12 controls and 12 patients used only for prediction (AUC=1, specificity=100% and sensitivity=100%). This multi-omics approach has revealed a biomarker signature for tuberculosis diagnosis that could be potentially used for developing a point-of-care diagnosis clinical test.

2023-03-11 | PXD037341 | Pride

CHEAR Christiani Biocrates

Project description:Human cord blood serum samples (200) were provided by David Christiani. The 200 study samples, total pool samples, and external CHEAR Plasma Reference Material samples were prepared and analyzed using the Biocrates AbsoluteIDQ p180 Kit.

2017-07-18 | ST000825 | MetabolomicsWorkbench

Hypothalamic gene expression in small litter vs control mouse (postnatal overnutrition)

Project description:Gene expression microarray profiling in adult (P180) small litter vs control mice.

2012-10-01 | GSE40616 | GEO

Fibroblast-specific genome-scale modelling predicts an imbalance in amino acid metabolism in Refsum disease

Project description:In this study, we reconstructed a fibroblast-specific genome-scale model based on the recently published, FAD-curated model, based on Recon3D reconstruction. To constrain the model we used transcriptomics, and proteomics data, which we obtained from healthy controls and Refsum disease patient fibroblasts incubated with phytol, a precursor of phytanic acid. Using this model, we investigated the metabolic phenotype of Refsum disease at the genome-scale, and we studied the effect of phytanic acid on cell metabolism. We identified 20 metabolites that were predicted to discriminate between Healthy and Refsum disease patients, several of which with a link to amino acid metabolism.

2020-03-21 | GSE138379 | GEO

An integrated metabolomics and lipidomics approach for the study of metabolic network and early diagnosis in cerebral infarction

Project description:Cerebral infarction (CI) remains a major cause of high mortality and long-term disability worldwide. The exploration of biomarkers and pathogenesis is crucial for early diagnosis of CI. Although the understanding of metabolic perturbations underlying CI has increased in recent years, the relationship between altered metabolites and disease pathogenesis has only been partially elucidated and requires further investigation. Here, we performed an integrated metabolomics and lipidomics analysis on 59 healthy subjects and 47 CI patients. Ultimately, 49 metabolites and 68 lipids biomarkers were identified and enriched in 24 disturbed pathways. The metabolic network revealed a significant interaction between altered lipids and other metabolites. Using ROC analysis, a panel of 3 polar metabolites and 7 lipids was optimized in training set, which was taurine, oleoylcarnitine, creatinine, PE(22:6/P-18:0), Cer 34:2, GlcCer(d18:0/18:0), DG 44:0, LysoPC(16:0), 22:6-OH/LysoPC and TAG58:7-FA22:4. Subsequently, a support vector machine (SVM) model was constructed and validated, which showed an excellent predictive ability in validation set. Thereby, the integrated metabolomics and lipidomics approach could contribute to a comprehensive understanding of the metabolic dyshomeostasis associated with the pathogenesis underlying CI. The present research may promote a deeper understanding and early diagnosis of CI in clinic.

2023-03-11 | PXD036199 | Pride

Metabolomic changes during active immunization with anti-METH vaccines.

Project description:A targeted metabolomics analysis was performed on serum samples from rats immunized with a methamphetamine-like hapten covalently bound to keyhole limpet hemocyanin (KLH) monomers, and controls. The subjects were approximately 300 g adult male Sprague Dawley rats. RTI International RCMRC received pre-immune serum from RI 11-03A (n=12) which is a matched control serum that was collected before starting immunizations, and week 17 bleeds from RI 11-03A (n=12), RI 11-03B (n=8), and RI 11-03C (n=12). The A-C nomenclature denotes A) complete antigen with adjuvant, B) complete antigen without adjuvant and C) only KLH carrier protein and adjuvant without a METH-like hapten. The rats’ serum samples were extracted and prepared for a combined flow injection (FIA) and LC-MS/MS assay (Biocrates AbsoluteIDQ® p180 kit). The Biocrates AbsoluteIDQ® p180 kit (Biocrates Life Sciences AG, Innsbruck, Austria) can quantitatively measure ~188 biologically relevant metabolites from five analyte groups (acylcarnitines, amino acids, biogenic amines, glycerophospho- and sphingolipids, and hexoses) on a triple quadrupole mass spectrometer.

2016-08-31 | ST000456 | MetabolomicsWorkbench

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data